Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TOXICITY EVALUATION OF DIFLUOROMETHYLORNITHINE - DOSES FOR CHEMOPREVENTION TRIALS
Autore:
LOPRINZI CL; MESSING EM; OFALLON JR; POON MA; LOVE RR; QUELLA SK; TRUMP DL; MORTON RF; NOVOTNY P;
Indirizzi:
MAYO CLIN & MAYO FDN,200 1ST ST SW ROCHESTER MN 55905 UNIV WISCONSIN MADISON WI 53792 SASKATCHEWAN CANC FDN,ALLAN BLIAR MEM CLIN REGINA SK S4T 7T1 CANADA PITTSBURGH CANC INST PITTSBURGH PA 15213 IOWA ONCOL RES ASSOCIAT,COMMUNITY CLIN ONCOL PROGRAM DES MOINES IA 50314
Titolo Testata:
Cancer epidemiology, biomarkers & prevention
fascicolo: 5, volume: 5, anno: 1996,
pagine: 371 - 374
SICI:
1055-9965(1996)5:5<371:TEOD-D>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
ORNITHINE DECARBOXYLASE ACTIVITY; ALPHA-DIFLUOROMETHYLORNITHINE; PHASE-I; INTESTINAL CARCINOGENESIS; POLYAMINE BIOSYNTHESIS; MAMMARY CARCINOGENESIS; INHIBITION; D,L-2-DIFLUOROMETHYLORNITHINE; 1-METHYL-1-NITROSOUREA; RATS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
C.L. Loprinzi et al., "TOXICITY EVALUATION OF DIFLUOROMETHYLORNITHINE - DOSES FOR CHEMOPREVENTION TRIALS", Cancer epidemiology, biomarkers & prevention, 5(5), 1996, pp. 371-374

Abstract

This intergroup trial was developed to determine the toxicity of relatively low doses of difluoromethylornithine (DFMO) administered to humans for 1 year, The goal was to find an appropriate DFMO dose for use in human chemoprevention trials, Patients with resected superficial bladder cancers were studied, Following stratification, they were randomized to daily DFMO doses of 0.125, 0.25, 0.5, or 1.0 g/day for a planned period of 1 year. Patients were followed closely for evidence of drug toxicity, Seventy-six patients were evenly randomized (19 per group) to receive each dose of DFMO. Forty-nine patients received DFMO for more than 200 days while 35 received the drug for greater than or equal to 350 days, No substantial drug-related toxicity was observed at any dose. DFMO doses of less than or equal to 1 g/day for periods up to 1 year appear to be without significant toxicity in most patients, This dose range may be appropriate for use in future human cancer chemoprevention trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:14:45